BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
Andrew G Li1,2, Elizabeth C Murphy2, Aedin C Culhane3,4
1Department of Genetics, Harvard Medical School, Boston, MA 02115; andrew_li@dfci.harvard.edu david_livingston@dfci.harvard.edu.
Abstract:
BRCA1 is an established breast and ovarian tumor suppressor gene that encodes multiple protein products whose individual contributions to human cancer suppression are poorly understood. BRCA1-IRIS (also known as "IRIS"), an alternatively spliced BRCA1 product and a chromatin-bound replication and transcription regulator, is overexpressed in various primary human cancers, including breast cancer, lung cancer, acute myeloid leukemia, and certain other carcinomas. Its naturally occurring overexpression can promote the metastasis of patient-derived xenograft (PDX) cells and other human cancer cells in mouse models. The IRIS-driven metastatic mechanism results from IRIS-dependent suppression of phosphatase and tensin homolog (PTEN) transcription, which in turn perturbs the PI3K/AKT/GSK-3β pathway leading to prolyl hydroxylase-independent HIF-1α stabilization and activation in a normoxic environment. Thus, despite the tumor-suppressing genetic origin of IRIS, its properties more closely resemble those of an oncoprotein that, when spontaneously overexpressed, can, paradoxically, drive human tumor progression.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Neuromuscular Junction And Blockade
The Eukaryotic Promoter Region
The Eukaryotic Promoter Region
Anaphase Promoting Complex
Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...


